nodes	percent_of_prediction	percent_of_DWPC	metapath
Nelarabine—Nucleic Acid Synthesis Inhibitors—Gemcitabine—urinary bladder cancer	0.276	0.515	CiPCiCtD
Nelarabine—Nucleic Acid Synthesis Inhibitors—Fluorouracil—urinary bladder cancer	0.259	0.485	CiPCiCtD
Nelarabine—POLA1—Gemcitabine—urinary bladder cancer	0.112	0.619	CbGbCtD
Nelarabine—DCK—Gemcitabine—urinary bladder cancer	0.0687	0.381	CbGbCtD
Nelarabine—Cytarabine—Gemcitabine—urinary bladder cancer	0.0605	0.35	CrCrCtD
Nelarabine—Azacitidine—Gemcitabine—urinary bladder cancer	0.0574	0.333	CrCrCtD
Nelarabine—Decitabine—Gemcitabine—urinary bladder cancer	0.0547	0.317	CrCrCtD
Nelarabine—DGUOK—prostate gland—urinary bladder cancer	0.00209	0.095	CbGeAlD
Nelarabine—DGUOK—seminal vesicle—urinary bladder cancer	0.00177	0.0803	CbGeAlD
Nelarabine—DGUOK—smooth muscle tissue—urinary bladder cancer	0.00148	0.0672	CbGeAlD
Nelarabine—DGUOK—renal system—urinary bladder cancer	0.00143	0.0647	CbGeAlD
Nelarabine—DGUOK—urethra—urinary bladder cancer	0.0014	0.0636	CbGeAlD
Nelarabine—POLA1—prostate gland—urinary bladder cancer	0.00129	0.0586	CbGeAlD
Nelarabine—ADA—prostate gland—urinary bladder cancer	0.0012	0.0543	CbGeAlD
Nelarabine—DGUOK—female reproductive system—urinary bladder cancer	0.00114	0.0518	CbGeAlD
Nelarabine—POLA1—seminal vesicle—urinary bladder cancer	0.00109	0.0495	CbGeAlD
Nelarabine—DGUOK—vagina—urinary bladder cancer	0.00103	0.0469	CbGeAlD
Nelarabine—POLA1—urethra—urinary bladder cancer	0.000864	0.0392	CbGeAlD
Nelarabine—ADA—renal system—urinary bladder cancer	0.000816	0.037	CbGeAlD
Nelarabine—DCK—prostate gland—urinary bladder cancer	0.000795	0.0361	CbGeAlD
Nelarabine—Cytarabine—POLB—urinary bladder cancer	0.000765	0.452	CrCbGaD
Nelarabine—DCK—seminal vesicle—urinary bladder cancer	0.000673	0.0305	CbGeAlD
Nelarabine—DGUOK—lymph node—urinary bladder cancer	0.000668	0.0303	CbGeAlD
Nelarabine—ADA—female reproductive system—urinary bladder cancer	0.000653	0.0297	CbGeAlD
Nelarabine—POLA1—vagina—urinary bladder cancer	0.000637	0.0289	CbGeAlD
Nelarabine—ADA—vagina—urinary bladder cancer	0.000591	0.0268	CbGeAlD
Nelarabine—DCK—urethra—urinary bladder cancer	0.000533	0.0242	CbGeAlD
Nelarabine—Clofarabine—RRM2—urinary bladder cancer	0.000488	0.288	CrCbGaD
Nelarabine—DCK—female reproductive system—urinary bladder cancer	0.000434	0.0197	CbGeAlD
Nelarabine—DCK—Doxorubicin—Valrubicin—urinary bladder cancer	0.000432	0.374	CbGdCrCtD
Nelarabine—DCK—Epirubicin—Valrubicin—urinary bladder cancer	0.000432	0.374	CbGdCrCtD
Nelarabine—POLA1—lymph node—urinary bladder cancer	0.000412	0.0187	CbGeAlD
Nelarabine—DCK—vagina—urinary bladder cancer	0.000393	0.0178	CbGeAlD
Nelarabine—ADA—lymph node—urinary bladder cancer	0.000382	0.0174	CbGeAlD
Nelarabine—ADA—Validated transcriptional targets of TAp63 isoforms—JAG1—urinary bladder cancer	0.000301	0.00824	CbGpPWpGaD
Nelarabine—ADA—C-MYB transcription factor network—BIRC3—urinary bladder cancer	0.000288	0.00787	CbGpPWpGaD
Nelarabine—DCK—Purine metabolism—GPX1—urinary bladder cancer	0.000287	0.00786	CbGpPWpGaD
Nelarabine—ADA—Validated transcriptional targets of TAp63 isoforms—NQO1—urinary bladder cancer	0.000286	0.00782	CbGpPWpGaD
Nelarabine—ADA—Nucleotide metabolism—RRM2—urinary bladder cancer	0.000286	0.00781	CbGpPWpGaD
Nelarabine—Cladribine—RRM2—urinary bladder cancer	0.00028	0.166	CrCbGaD
Nelarabine—DCK—Nucleotide metabolism—RRM2—urinary bladder cancer	0.000264	0.00721	CbGpPWpGaD
Nelarabine—DCK—lymph node—urinary bladder cancer	0.000254	0.0115	CbGeAlD
Nelarabine—ADA—C-MYB transcription factor network—MPO—urinary bladder cancer	0.000246	0.00673	CbGpPWpGaD
Nelarabine—DCK—Retinoblastoma (RB) in Cancer—RRM2—urinary bladder cancer	0.000242	0.0066	CbGpPWpGaD
Nelarabine—ADA—Circadian rythm related genes—KMT2A—urinary bladder cancer	0.000241	0.00658	CbGpPWpGaD
Nelarabine—POLA1—Telomere Maintenance—LIG1—urinary bladder cancer	0.000234	0.00641	CbGpPWpGaD
Nelarabine—POLA1—E2F mediated regulation of DNA replication—CCNE1—urinary bladder cancer	0.000226	0.00619	CbGpPWpGaD
Nelarabine—POLA1—E2F transcription factor network—XRCC1—urinary bladder cancer	0.000226	0.00618	CbGpPWpGaD
Nelarabine—POLA1—E2F mediated regulation of DNA replication—TYMS—urinary bladder cancer	0.000222	0.00608	CbGpPWpGaD
Nelarabine—POLA1—Extension of Telomeres—TERT—urinary bladder cancer	0.000215	0.00587	CbGpPWpGaD
Nelarabine—DCK—Retinoblastoma (RB) in Cancer—SMC1A—urinary bladder cancer	0.000205	0.00562	CbGpPWpGaD
Nelarabine—POLA1—E2F transcription factor network—RRM2—urinary bladder cancer	0.000203	0.00556	CbGpPWpGaD
Nelarabine—POLA1—Synthesis of DNA—LIG1—urinary bladder cancer	0.000198	0.00543	CbGpPWpGaD
Nelarabine—ADA—Validated transcriptional targets of TAp63 isoforms—FAS—urinary bladder cancer	0.000197	0.00538	CbGpPWpGaD
Nelarabine—POLA1—Chromosome Maintenance—LIG1—urinary bladder cancer	0.000195	0.00534	CbGpPWpGaD
Nelarabine—ADA—Validated transcriptional targets of deltaNp63 isoforms—ATM—urinary bladder cancer	0.000194	0.00531	CbGpPWpGaD
Nelarabine—POLA1—DNA Replication—LIG1—urinary bladder cancer	0.000186	0.00509	CbGpPWpGaD
Nelarabine—POLA1—Retinoblastoma (RB) in Cancer—RRM2—urinary bladder cancer	0.000177	0.00483	CbGpPWpGaD
Nelarabine—DGUOK—Metabolism—GSTZ1—urinary bladder cancer	0.000174	0.00477	CbGpPWpGaD
Nelarabine—ADA—Nucleotide metabolism—TYMS—urinary bladder cancer	0.000165	0.00452	CbGpPWpGaD
Nelarabine—DGUOK—Metabolism—GSTO2—urinary bladder cancer	0.000165	0.00452	CbGpPWpGaD
Nelarabine—DGUOK—Metabolism—NAT1—urinary bladder cancer	0.000165	0.00452	CbGpPWpGaD
Nelarabine—POLA1—S Phase—LIG1—urinary bladder cancer	0.000163	0.00445	CbGpPWpGaD
Nelarabine—POLA1—S Phase—STAG2—urinary bladder cancer	0.000163	0.00445	CbGpPWpGaD
Nelarabine—Adenosine monophosphate—SRC—urinary bladder cancer	0.00016	0.0947	CrCbGaD
Nelarabine—ADA—Nucleotide metabolism—GPX1—urinary bladder cancer	0.000156	0.00428	CbGpPWpGaD
Nelarabine—ADA—C-MYB transcription factor network—NCOR1—urinary bladder cancer	0.000154	0.00421	CbGpPWpGaD
Nelarabine—ADA—C-MYB transcription factor network—GSTM1—urinary bladder cancer	0.000154	0.00421	CbGpPWpGaD
Nelarabine—DCK—Nucleotide metabolism—TYMS—urinary bladder cancer	0.000153	0.00417	CbGpPWpGaD
Nelarabine—DGUOK—Metabolism—UGT2B7—urinary bladder cancer	0.000151	0.00413	CbGpPWpGaD
Nelarabine—POLA1—E2F mediated regulation of DNA replication—RB1—urinary bladder cancer	0.000151	0.00412	CbGpPWpGaD
Nelarabine—DCK—Doxorubicin—Epirubicin—urinary bladder cancer	0.00015	0.13	CbGdCrCtD
Nelarabine—POLA1—Retinoblastoma (RB) in Cancer—SMC1A—urinary bladder cancer	0.00015	0.00411	CbGpPWpGaD
Nelarabine—ADA—Validated transcriptional targets of deltaNp63 isoforms—CDKN2A—urinary bladder cancer	0.000148	0.00404	CbGpPWpGaD
Nelarabine—POLA1—G1/S Transition—RRM2—urinary bladder cancer	0.000148	0.00404	CbGpPWpGaD
Nelarabine—ADA—p73 transcription factor network—FAS—urinary bladder cancer	0.000145	0.00397	CbGpPWpGaD
Nelarabine—DCK—Nucleotide metabolism—GPX1—urinary bladder cancer	0.000144	0.00395	CbGpPWpGaD
Nelarabine—DCK—Retinoblastoma (RB) in Cancer—CCNE1—urinary bladder cancer	0.000142	0.00389	CbGpPWpGaD
Nelarabine—DCK—Retinoblastoma (RB) in Cancer—TYMS—urinary bladder cancer	0.00014	0.00382	CbGpPWpGaD
Nelarabine—DCK—Epirubicin—Doxorubicin—urinary bladder cancer	0.000139	0.121	CbGdCrCtD
Nelarabine—DGUOK—Metabolism—CYP4B1—urinary bladder cancer	0.000136	0.00372	CbGpPWpGaD
Nelarabine—ADA—Validated transcriptional targets of TAp63 isoforms—CDKN2A—urinary bladder cancer	0.000132	0.00362	CbGpPWpGaD
Nelarabine—DGUOK—Metabolism—SLC19A1—urinary bladder cancer	0.000129	0.00351	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle—SMC1B—urinary bladder cancer	0.000128	0.00349	CbGpPWpGaD
Nelarabine—DGUOK—Metabolism—PRSS3—urinary bladder cancer	0.000125	0.00342	CbGpPWpGaD
Nelarabine—POLA1—Mitotic G1-G1/S phases—RRM2—urinary bladder cancer	0.000124	0.0034	CbGpPWpGaD
Nelarabine—POLA1—E2F transcription factor network—CCNE1—urinary bladder cancer	0.00012	0.00328	CbGpPWpGaD
Nelarabine—POLA1—E2F transcription factor network—TYMS—urinary bladder cancer	0.000118	0.00322	CbGpPWpGaD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—LIG1—urinary bladder cancer	0.000114	0.00313	CbGpPWpGaD
Nelarabine—POLA1—S Phase—SMC1A—urinary bladder cancer	0.000114	0.00312	CbGpPWpGaD
Nelarabine—ADA—p73 transcription factor network—RB1—urinary bladder cancer	0.000111	0.00303	CbGpPWpGaD
Nelarabine—DCK—Retinoblastoma (RB) in Cancer—CDK4—urinary bladder cancer	0.000109	0.00298	CbGpPWpGaD
Nelarabine—ADA—Validated transcriptional targets of TAp63 isoforms—CDKN1A—urinary bladder cancer	0.000108	0.00295	CbGpPWpGaD
Nelarabine—ADA—C-MYB transcription factor network—CREBBP—urinary bladder cancer	0.000106	0.0029	CbGpPWpGaD
Nelarabine—POLA1—Retinoblastoma (RB) in Cancer—CCNE1—urinary bladder cancer	0.000104	0.00285	CbGpPWpGaD
Nelarabine—ADA—Validated transcriptional targets of TAp63 isoforms—EP300—urinary bladder cancer	0.000103	0.00281	CbGpPWpGaD
Nelarabine—POLA1—Retinoblastoma (RB) in Cancer—TYMS—urinary bladder cancer	0.000102	0.0028	CbGpPWpGaD
Nelarabine—DGUOK—Metabolism—TYMP—urinary bladder cancer	0.0001	0.00274	CbGpPWpGaD
Nelarabine—POLA1—Mitotic M-M/G1 phases—ESPL1—urinary bladder cancer	9.77e-05	0.00267	CbGpPWpGaD
Nelarabine—POLA1—Telomere Maintenance—TERT—urinary bladder cancer	9.73e-05	0.00266	CbGpPWpGaD
Nelarabine—POLA1—E2F transcription factor network—PLAU—urinary bladder cancer	9.71e-05	0.00266	CbGpPWpGaD
Nelarabine—DCK—Retinoblastoma (RB) in Cancer—RB1—urinary bladder cancer	9.48e-05	0.00259	CbGpPWpGaD
Nelarabine—ADA—C-MYB transcription factor network—CDKN2A—urinary bladder cancer	9.29e-05	0.00254	CbGpPWpGaD
Nelarabine—POLA1—E2F transcription factor network—ATM—urinary bladder cancer	9.22e-05	0.00252	CbGpPWpGaD
Nelarabine—DGUOK—Metabolism—NAT2—urinary bladder cancer	9.05e-05	0.00248	CbGpPWpGaD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—HPGDS—urinary bladder cancer	8.73e-05	0.00239	CbGpPWpGaD
Nelarabine—POLA1—G1/S Transition—CCNE1—urinary bladder cancer	8.7e-05	0.00238	CbGpPWpGaD
Nelarabine—ADA—C-MYB transcription factor network—PTGS2—urinary bladder cancer	8.68e-05	0.00237	CbGpPWpGaD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—IGFBP3—urinary bladder cancer	8.67e-05	0.00237	CbGpPWpGaD
Nelarabine—POLA1—G1/S Transition—TYMS—urinary bladder cancer	8.54e-05	0.00234	CbGpPWpGaD
Nelarabine—POLA1—Chromosome Maintenance—TERT—urinary bladder cancer	8.1e-05	0.00222	CbGpPWpGaD
Nelarabine—POLA1—E2F transcription factor network—CREBBP—urinary bladder cancer	8.01e-05	0.00219	CbGpPWpGaD
Nelarabine—POLA1—E2F transcription factor network—RB1—urinary bladder cancer	7.98e-05	0.00218	CbGpPWpGaD
Nelarabine—POLA1—Retinoblastoma (RB) in Cancer—CDK4—urinary bladder cancer	7.98e-05	0.00218	CbGpPWpGaD
Nelarabine—ADA—p73 transcription factor network—CDKN1A—urinary bladder cancer	7.97e-05	0.00218	CbGpPWpGaD
Nelarabine—POLA1—S Phase—CCNE1—urinary bladder cancer	7.9e-05	0.00216	CbGpPWpGaD
Nelarabine—ADA—C-MYB transcription factor network—CCND1—urinary bladder cancer	7.84e-05	0.00215	CbGpPWpGaD
Nelarabine—DGUOK—Metabolism—RRM2—urinary bladder cancer	7.82e-05	0.00214	CbGpPWpGaD
Nelarabine—ADA—Circadian rythm related genes—TYMS—urinary bladder cancer	7.75e-05	0.00212	CbGpPWpGaD
Nelarabine—ADA—Circadian rythm related genes—NCOR1—urinary bladder cancer	7.66e-05	0.0021	CbGpPWpGaD
Nelarabine—ADA—C-MYB transcription factor network—CDKN1A—urinary bladder cancer	7.59e-05	0.00208	CbGpPWpGaD
Nelarabine—ADA—p73 transcription factor network—EP300—urinary bladder cancer	7.58e-05	0.00207	CbGpPWpGaD
Nelarabine—POLA1—Mitotic M-M/G1 phases—STAG2—urinary bladder cancer	7.41e-05	0.00203	CbGpPWpGaD
Nelarabine—POLA1—Mitotic G1-G1/S phases—CCNE1—urinary bladder cancer	7.33e-05	0.002	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle, Mitotic—ESPL1—urinary bladder cancer	7.31e-05	0.002	CbGpPWpGaD
Nelarabine—DGUOK—Metabolism—HPGDS—urinary bladder cancer	7.24e-05	0.00198	CbGpPWpGaD
Nelarabine—DGUOK—Metabolism—ENO2—urinary bladder cancer	7.24e-05	0.00198	CbGpPWpGaD
Nelarabine—ADA—C-MYB transcription factor network—EP300—urinary bladder cancer	7.22e-05	0.00197	CbGpPWpGaD
Nelarabine—POLA1—Mitotic G1-G1/S phases—TYMS—urinary bladder cancer	7.2e-05	0.00197	CbGpPWpGaD
Nelarabine—DCK—Retinoblastoma (RB) in Cancer—CCND1—urinary bladder cancer	7.04e-05	0.00192	CbGpPWpGaD
Nelarabine—DGUOK—Metabolism—GSTT1—urinary bladder cancer	7.02e-05	0.00192	CbGpPWpGaD
Nelarabine—POLA1—E2F transcription factor network—CDKN2A—urinary bladder cancer	7.02e-05	0.00192	CbGpPWpGaD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—ESR2—urinary bladder cancer	6.98e-05	0.00191	CbGpPWpGaD
Nelarabine—POLA1—Retinoblastoma (RB) in Cancer—RB1—urinary bladder cancer	6.94e-05	0.0019	CbGpPWpGaD
Nelarabine—ADA—Circadian rythm related genes—FAS—urinary bladder cancer	6.87e-05	0.00188	CbGpPWpGaD
Nelarabine—DCK—Retinoblastoma (RB) in Cancer—CDKN1A—urinary bladder cancer	6.81e-05	0.00186	CbGpPWpGaD
Nelarabine—ADA—p73 transcription factor network—MYC—urinary bladder cancer	6.61e-05	0.00181	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle—ESPL1—urinary bladder cancer	6.54e-05	0.00179	CbGpPWpGaD
Nelarabine—POLA1—Synthesis of DNA—RB1—urinary bladder cancer	6.41e-05	0.00175	CbGpPWpGaD
Nelarabine—ADA—C-MYB transcription factor network—MYC—urinary bladder cancer	6.29e-05	0.00172	CbGpPWpGaD
Nelarabine—POLA1—S Phase—CDK4—urinary bladder cancer	6.05e-05	0.00165	CbGpPWpGaD
Nelarabine—ADA—Circadian rythm related genes—CDK4—urinary bladder cancer	6.04e-05	0.00165	CbGpPWpGaD
Nelarabine—POLA1—DNA Replication—RB1—urinary bladder cancer	6.01e-05	0.00164	CbGpPWpGaD
Nelarabine—DGUOK—Metabolism—NQO1—urinary bladder cancer	5.83e-05	0.0016	CbGpPWpGaD
Nelarabine—ADA—C-MYB transcription factor network—KRAS—urinary bladder cancer	5.81e-05	0.00159	CbGpPWpGaD
Nelarabine—POLA1—G1/S Transition—RB1—urinary bladder cancer	5.79e-05	0.00158	CbGpPWpGaD
Nelarabine—ADA—Metabolism—GSTZ1—urinary bladder cancer	5.79e-05	0.00158	CbGpPWpGaD
Nelarabine—POLA1—E2F transcription factor network—CDKN1A—urinary bladder cancer	5.74e-05	0.00157	CbGpPWpGaD
Nelarabine—DCK—Retinoblastoma (RB) in Cancer—MYC—urinary bladder cancer	5.65e-05	0.00154	CbGpPWpGaD
Nelarabine—POLA1—Mitotic G1-G1/S phases—CDK4—urinary bladder cancer	5.61e-05	0.00154	CbGpPWpGaD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—CCNE1—urinary bladder cancer	5.55e-05	0.00152	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle, Mitotic—STAG2—urinary bladder cancer	5.54e-05	0.00151	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle, Mitotic—LIG1—urinary bladder cancer	5.54e-05	0.00151	CbGpPWpGaD
Nelarabine—ADA—Circadian rythm related genes—PPARG—urinary bladder cancer	5.49e-05	0.0015	CbGpPWpGaD
Nelarabine—ADA—Metabolism—GSTO2—urinary bladder cancer	5.49e-05	0.0015	CbGpPWpGaD
Nelarabine—ADA—Metabolism—NAT1—urinary bladder cancer	5.49e-05	0.0015	CbGpPWpGaD
Nelarabine—POLA1—E2F transcription factor network—EP300—urinary bladder cancer	5.46e-05	0.00149	CbGpPWpGaD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—TYMS—urinary bladder cancer	5.45e-05	0.00149	CbGpPWpGaD
Nelarabine—DCK—Metabolism—GSTZ1—urinary bladder cancer	5.34e-05	0.00146	CbGpPWpGaD
Nelarabine—POLA1—S Phase—RB1—urinary bladder cancer	5.26e-05	0.00144	CbGpPWpGaD
Nelarabine—POLA1—Mitotic M-M/G1 phases—SMC1A—urinary bladder cancer	5.19e-05	0.00142	CbGpPWpGaD
Nelarabine—POLA1—Retinoblastoma (RB) in Cancer—CCND1—urinary bladder cancer	5.15e-05	0.00141	CbGpPWpGaD
Nelarabine—DCK—Metabolism—GSTO2—urinary bladder cancer	5.06e-05	0.00138	CbGpPWpGaD
Nelarabine—DCK—Metabolism—NAT1—urinary bladder cancer	5.06e-05	0.00138	CbGpPWpGaD
Nelarabine—ADA—Metabolism—UGT2B7—urinary bladder cancer	5.02e-05	0.00137	CbGpPWpGaD
Nelarabine—POLA1—Retinoblastoma (RB) in Cancer—CDKN1A—urinary bladder cancer	4.98e-05	0.00136	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle—STAG2—urinary bladder cancer	4.95e-05	0.00135	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle—LIG1—urinary bladder cancer	4.95e-05	0.00135	CbGpPWpGaD
Nelarabine—ADA—C-MYB transcription factor network—HRAS—urinary bladder cancer	4.94e-05	0.00135	CbGpPWpGaD
Nelarabine—POLA1—Mitotic G1-G1/S phases—RB1—urinary bladder cancer	4.88e-05	0.00133	CbGpPWpGaD
Nelarabine—DGUOK—Metabolism—GSTP1—urinary bladder cancer	4.87e-05	0.00133	CbGpPWpGaD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—FAS—urinary bladder cancer	4.83e-05	0.00132	CbGpPWpGaD
Nelarabine—POLA1—E2F transcription factor network—MYC—urinary bladder cancer	4.76e-05	0.0013	CbGpPWpGaD
Nelarabine—DCK—Retinoblastoma (RB) in Cancer—TP53—urinary bladder cancer	4.64e-05	0.00127	CbGpPWpGaD
Nelarabine—DCK—Metabolism—UGT2B7—urinary bladder cancer	4.63e-05	0.00127	CbGpPWpGaD
Nelarabine—POLA1—Synthesis of DNA—CDKN1A—urinary bladder cancer	4.61e-05	0.00126	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle, Mitotic—RRM2—urinary bladder cancer	4.56e-05	0.00125	CbGpPWpGaD
Nelarabine—DGUOK—Metabolism—TYMS—urinary bladder cancer	4.52e-05	0.00124	CbGpPWpGaD
Nelarabine—ADA—Metabolism—CYP4B1—urinary bladder cancer	4.52e-05	0.00124	CbGpPWpGaD
Nelarabine—DGUOK—Metabolism—GSTM1—urinary bladder cancer	4.47e-05	0.00122	CbGpPWpGaD
Nelarabine—DGUOK—Metabolism—NCOR1—urinary bladder cancer	4.47e-05	0.00122	CbGpPWpGaD
Nelarabine—POLA1—DNA Replication—CDKN1A—urinary bladder cancer	4.32e-05	0.00118	CbGpPWpGaD
Nelarabine—POLA1—Mitotic G1-G1/S phases—CDKN2A—urinary bladder cancer	4.29e-05	0.00117	CbGpPWpGaD
Nelarabine—DGUOK—Metabolism—GPX1—urinary bladder cancer	4.28e-05	0.00117	CbGpPWpGaD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—ATM—urinary bladder cancer	4.27e-05	0.00117	CbGpPWpGaD
Nelarabine—ADA—Metabolism—SLC19A1—urinary bladder cancer	4.27e-05	0.00117	CbGpPWpGaD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—CDK4—urinary bladder cancer	4.25e-05	0.00116	CbGpPWpGaD
Nelarabine—Hypokalaemia—Epirubicin—urinary bladder cancer	4.25e-05	0.000842	CcSEcCtD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—ESR1—urinary bladder cancer	4.24e-05	0.00116	CbGpPWpGaD
Nelarabine—Paraesthesia—Fluorouracil—urinary bladder cancer	4.23e-05	0.000839	CcSEcCtD
Nelarabine—DGUOK—Metabolism—ERCC2—urinary bladder cancer	4.2e-05	0.00115	CbGpPWpGaD
Nelarabine—Aspartate aminotransferase increased—Epirubicin—urinary bladder cancer	4.2e-05	0.000833	CcSEcCtD
Nelarabine—Dyspnoea—Fluorouracil—urinary bladder cancer	4.2e-05	0.000833	CcSEcCtD
Nelarabine—Somnolence—Fluorouracil—urinary bladder cancer	4.19e-05	0.00083	CcSEcCtD
Nelarabine—Hypotension—Cisplatin—urinary bladder cancer	4.17e-05	0.000827	CcSEcCtD
Nelarabine—DCK—Metabolism—CYP4B1—urinary bladder cancer	4.17e-05	0.00114	CbGpPWpGaD
Nelarabine—Decreased appetite—Gemcitabine—urinary bladder cancer	4.16e-05	0.000826	CcSEcCtD
Nelarabine—POLA1—G1/S Transition—CDKN1A—urinary bladder cancer	4.16e-05	0.00114	CbGpPWpGaD
Nelarabine—ADA—Metabolism—PRSS3—urinary bladder cancer	4.16e-05	0.00114	CbGpPWpGaD
Nelarabine—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	4.14e-05	0.00082	CcSEcCtD
Nelarabine—POLA1—Retinoblastoma (RB) in Cancer—MYC—urinary bladder cancer	4.13e-05	0.00113	CbGpPWpGaD
Nelarabine—Fatigue—Gemcitabine—urinary bladder cancer	4.13e-05	0.000819	CcSEcCtD
Nelarabine—Confusional state—Etoposide—urinary bladder cancer	4.13e-05	0.000818	CcSEcCtD
Nelarabine—Muscular weakness—Epirubicin—urinary bladder cancer	4.12e-05	0.000816	CcSEcCtD
Nelarabine—Pain—Gemcitabine—urinary bladder cancer	4.1e-05	0.000812	CcSEcCtD
Nelarabine—Constipation—Gemcitabine—urinary bladder cancer	4.1e-05	0.000812	CcSEcCtD
Nelarabine—Decreased appetite—Fluorouracil—urinary bladder cancer	4.09e-05	0.000812	CcSEcCtD
Nelarabine—Asthenia—Thiotepa—urinary bladder cancer	4.09e-05	0.00081	CcSEcCtD
Nelarabine—POLA1—Cell Cycle—RRM2—urinary bladder cancer	4.08e-05	0.00112	CbGpPWpGaD
Nelarabine—Musculoskeletal discomfort—Cisplatin—urinary bladder cancer	4.07e-05	0.000807	CcSEcCtD
Nelarabine—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	4.07e-05	0.000806	CcSEcCtD
Nelarabine—Infection—Etoposide—urinary bladder cancer	4.06e-05	0.000806	CcSEcCtD
Nelarabine—Abdominal distension—Epirubicin—urinary bladder cancer	4.06e-05	0.000805	CcSEcCtD
Nelarabine—Ataxia—Doxorubicin—urinary bladder cancer	4.06e-05	0.000805	CcSEcCtD
Nelarabine—Blood creatinine increased—Doxorubicin—urinary bladder cancer	4.04e-05	0.000802	CcSEcCtD
Nelarabine—Neutropenia—Methotrexate—urinary bladder cancer	4.03e-05	0.000799	CcSEcCtD
Nelarabine—Pain—Fluorouracil—urinary bladder cancer	4.03e-05	0.000799	CcSEcCtD
Nelarabine—Dehydration—Doxorubicin—urinary bladder cancer	4.01e-05	0.000796	CcSEcCtD
Nelarabine—Paraesthesia—Cisplatin—urinary bladder cancer	4.01e-05	0.000795	CcSEcCtD
Nelarabine—Thrombocytopenia—Etoposide—urinary bladder cancer	4.01e-05	0.000794	CcSEcCtD
Nelarabine—Dyspnoea—Cisplatin—urinary bladder cancer	3.98e-05	0.000789	CcSEcCtD
Nelarabine—DGUOK—Metabolism—MTHFR—urinary bladder cancer	3.95e-05	0.00108	CbGpPWpGaD
Nelarabine—Feeling abnormal—Gemcitabine—urinary bladder cancer	3.95e-05	0.000783	CcSEcCtD
Nelarabine—DCK—Metabolism—SLC19A1—urinary bladder cancer	3.94e-05	0.00108	CbGpPWpGaD
Nelarabine—Hypokalaemia—Doxorubicin—urinary bladder cancer	3.93e-05	0.000779	CcSEcCtD
Nelarabine—POLA1—S Phase—CCND1—urinary bladder cancer	3.91e-05	0.00107	CbGpPWpGaD
Nelarabine—Anorexia—Etoposide—urinary bladder cancer	3.9e-05	0.000773	CcSEcCtD
Nelarabine—Diarrhoea—Thiotepa—urinary bladder cancer	3.9e-05	0.000773	CcSEcCtD
Nelarabine—Aspartate aminotransferase increased—Doxorubicin—urinary bladder cancer	3.89e-05	0.000771	CcSEcCtD
Nelarabine—Decreased appetite—Cisplatin—urinary bladder cancer	3.88e-05	0.00077	CcSEcCtD
Nelarabine—Feeling abnormal—Fluorouracil—urinary bladder cancer	3.88e-05	0.00077	CcSEcCtD
Nelarabine—POLA1—Cell Cycle, Mitotic—SMC1A—urinary bladder cancer	3.88e-05	0.00106	CbGpPWpGaD
Nelarabine—Pneumonia—Methotrexate—urinary bladder cancer	3.86e-05	0.000766	CcSEcCtD
Nelarabine—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	3.86e-05	0.000764	CcSEcCtD
Nelarabine—Infestation NOS—Methotrexate—urinary bladder cancer	3.84e-05	0.000762	CcSEcCtD
Nelarabine—Infestation—Methotrexate—urinary bladder cancer	3.84e-05	0.000762	CcSEcCtD
Nelarabine—DCK—Metabolism—PRSS3—urinary bladder cancer	3.84e-05	0.00105	CbGpPWpGaD
Nelarabine—Depression—Methotrexate—urinary bladder cancer	3.83e-05	0.00076	CcSEcCtD
Nelarabine—Hypotension—Etoposide—urinary bladder cancer	3.82e-05	0.000758	CcSEcCtD
Nelarabine—Pain—Cisplatin—urinary bladder cancer	3.82e-05	0.000757	CcSEcCtD
Nelarabine—Muscular weakness—Doxorubicin—urinary bladder cancer	3.81e-05	0.000755	CcSEcCtD
Nelarabine—Body temperature increased—Gemcitabine—urinary bladder cancer	3.79e-05	0.000751	CcSEcCtD
Nelarabine—POLA1—S Phase—CDKN1A—urinary bladder cancer	3.78e-05	0.00103	CbGpPWpGaD
Nelarabine—Neutropenia—Epirubicin—urinary bladder cancer	3.77e-05	0.000748	CcSEcCtD
Nelarabine—ADA—Circadian rythm related genes—PTEN—urinary bladder cancer	3.77e-05	0.00103	CbGpPWpGaD
Nelarabine—Dizziness—Thiotepa—urinary bladder cancer	3.77e-05	0.000747	CcSEcCtD
Nelarabine—Abdominal distension—Doxorubicin—urinary bladder cancer	3.76e-05	0.000745	CcSEcCtD
Nelarabine—Stomatitis—Methotrexate—urinary bladder cancer	3.75e-05	0.000743	CcSEcCtD
Nelarabine—Body temperature increased—Fluorouracil—urinary bladder cancer	3.72e-05	0.000738	CcSEcCtD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—CREBBP—urinary bladder cancer	3.71e-05	0.00102	CbGpPWpGaD
Nelarabine—Feeling abnormal—Cisplatin—urinary bladder cancer	3.68e-05	0.00073	CcSEcCtD
Nelarabine—Paraesthesia—Etoposide—urinary bladder cancer	3.67e-05	0.000728	CcSEcCtD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—IGF1—urinary bladder cancer	3.67e-05	0.001	CbGpPWpGaD
Nelarabine—Dyspnoea—Etoposide—urinary bladder cancer	3.65e-05	0.000723	CcSEcCtD
Nelarabine—Hyperglycaemia—Epirubicin—urinary bladder cancer	3.64e-05	0.000721	CcSEcCtD
Nelarabine—Somnolence—Etoposide—urinary bladder cancer	3.64e-05	0.000721	CcSEcCtD
Nelarabine—Hepatobiliary disease—Methotrexate—urinary bladder cancer	3.63e-05	0.00072	CcSEcCtD
Nelarabine—POLA1—Mitotic G1-G1/S phases—CCND1—urinary bladder cancer	3.63e-05	0.000991	CbGpPWpGaD
Nelarabine—Epistaxis—Methotrexate—urinary bladder cancer	3.62e-05	0.000719	CcSEcCtD
Nelarabine—Vomiting—Thiotepa—urinary bladder cancer	3.62e-05	0.000718	CcSEcCtD
Nelarabine—Pneumonia—Epirubicin—urinary bladder cancer	3.62e-05	0.000717	CcSEcCtD
Nelarabine—Infestation—Epirubicin—urinary bladder cancer	3.6e-05	0.000713	CcSEcCtD
Nelarabine—Infestation NOS—Epirubicin—urinary bladder cancer	3.6e-05	0.000713	CcSEcCtD
Nelarabine—ADA—Circadian rythm related genes—EP300—urinary bladder cancer	3.59e-05	0.000982	CbGpPWpGaD
Nelarabine—Headache—Thiotepa—urinary bladder cancer	3.57e-05	0.000707	CcSEcCtD
Nelarabine—Decreased appetite—Etoposide—urinary bladder cancer	3.56e-05	0.000705	CcSEcCtD
Nelarabine—Gastrointestinal disorder—Etoposide—urinary bladder cancer	3.53e-05	0.0007	CcSEcCtD
Nelarabine—Body temperature increased—Cisplatin—urinary bladder cancer	3.53e-05	0.0007	CcSEcCtD
Nelarabine—Fatigue—Etoposide—urinary bladder cancer	3.53e-05	0.000699	CcSEcCtD
Nelarabine—Neuropathy peripheral—Epirubicin—urinary bladder cancer	3.52e-05	0.000699	CcSEcCtD
Nelarabine—POLA1—Mitotic G1-G1/S phases—CDKN1A—urinary bladder cancer	3.51e-05	0.000959	CbGpPWpGaD
Nelarabine—Stomatitis—Epirubicin—urinary bladder cancer	3.5e-05	0.000695	CcSEcCtD
Nelarabine—Pain—Etoposide—urinary bladder cancer	3.5e-05	0.000694	CcSEcCtD
Nelarabine—Constipation—Etoposide—urinary bladder cancer	3.5e-05	0.000694	CcSEcCtD
Nelarabine—Neutropenia—Doxorubicin—urinary bladder cancer	3.49e-05	0.000692	CcSEcCtD
Nelarabine—POLA1—Cell Cycle—SMC1A—urinary bladder cancer	3.47e-05	0.000948	CbGpPWpGaD
Nelarabine—POLA1—G1/S Transition—MYC—urinary bladder cancer	3.45e-05	0.000944	CbGpPWpGaD
Nelarabine—Asthenia—Gemcitabine—urinary bladder cancer	3.44e-05	0.000682	CcSEcCtD
Nelarabine—Urinary tract disorder—Methotrexate—urinary bladder cancer	3.41e-05	0.000675	CcSEcCtD
Nelarabine—Hepatobiliary disease—Epirubicin—urinary bladder cancer	3.4e-05	0.000674	CcSEcCtD
Nelarabine—POLA1—Retinoblastoma (RB) in Cancer—TP53—urinary bladder cancer	3.39e-05	0.000928	CbGpPWpGaD
Nelarabine—Epistaxis—Epirubicin—urinary bladder cancer	3.39e-05	0.000672	CcSEcCtD
Nelarabine—Nausea—Thiotepa—urinary bladder cancer	3.38e-05	0.000671	CcSEcCtD
Nelarabine—Urethral disorder—Methotrexate—urinary bladder cancer	3.38e-05	0.00067	CcSEcCtD
Nelarabine—Sinusitis—Epirubicin—urinary bladder cancer	3.37e-05	0.000669	CcSEcCtD
Nelarabine—Feeling abnormal—Etoposide—urinary bladder cancer	3.37e-05	0.000668	CcSEcCtD
Nelarabine—Hyperglycaemia—Doxorubicin—urinary bladder cancer	3.37e-05	0.000667	CcSEcCtD
Nelarabine—Pneumonia—Doxorubicin—urinary bladder cancer	3.35e-05	0.000663	CcSEcCtD
Nelarabine—Gastrointestinal pain—Etoposide—urinary bladder cancer	3.35e-05	0.000663	CcSEcCtD
Nelarabine—Infestation—Doxorubicin—urinary bladder cancer	3.33e-05	0.00066	CcSEcCtD
Nelarabine—Infestation NOS—Doxorubicin—urinary bladder cancer	3.33e-05	0.00066	CcSEcCtD
Nelarabine—ADA—Metabolism—TYMP—urinary bladder cancer	3.32e-05	0.000909	CbGpPWpGaD
Nelarabine—Diarrhoea—Gemcitabine—urinary bladder cancer	3.28e-05	0.00065	CcSEcCtD
Nelarabine—Neuropathy peripheral—Doxorubicin—urinary bladder cancer	3.26e-05	0.000647	CcSEcCtD
Nelarabine—Stomatitis—Doxorubicin—urinary bladder cancer	3.24e-05	0.000643	CcSEcCtD
Nelarabine—Abdominal pain—Etoposide—urinary bladder cancer	3.23e-05	0.000641	CcSEcCtD
Nelarabine—Body temperature increased—Etoposide—urinary bladder cancer	3.23e-05	0.000641	CcSEcCtD
Nelarabine—Eye disorder—Methotrexate—urinary bladder cancer	3.22e-05	0.000639	CcSEcCtD
Nelarabine—Diarrhoea—Fluorouracil—urinary bladder cancer	3.22e-05	0.000639	CcSEcCtD
Nelarabine—Hypoaesthesia—Epirubicin—urinary bladder cancer	3.21e-05	0.000637	CcSEcCtD
Nelarabine—DGUOK—Metabolism—PPARG—urinary bladder cancer	3.2e-05	0.000876	CbGpPWpGaD
Nelarabine—Asthenia—Cisplatin—urinary bladder cancer	3.2e-05	0.000635	CcSEcCtD
Nelarabine—Cardiac disorder—Methotrexate—urinary bladder cancer	3.2e-05	0.000635	CcSEcCtD
Nelarabine—Urinary tract disorder—Epirubicin—urinary bladder cancer	3.19e-05	0.000632	CcSEcCtD
Nelarabine—Oedema peripheral—Epirubicin—urinary bladder cancer	3.18e-05	0.00063	CcSEcCtD
Nelarabine—Connective tissue disorder—Epirubicin—urinary bladder cancer	3.17e-05	0.000629	CcSEcCtD
Nelarabine—Urethral disorder—Epirubicin—urinary bladder cancer	3.16e-05	0.000627	CcSEcCtD
Nelarabine—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	3.15e-05	0.000624	CcSEcCtD
Nelarabine—Epistaxis—Doxorubicin—urinary bladder cancer	3.14e-05	0.000622	CcSEcCtD
Nelarabine—POLA1—S Phase—MYC—urinary bladder cancer	3.13e-05	0.000857	CbGpPWpGaD
Nelarabine—Angiopathy—Methotrexate—urinary bladder cancer	3.13e-05	0.00062	CcSEcCtD
Nelarabine—Sinusitis—Doxorubicin—urinary bladder cancer	3.12e-05	0.000619	CcSEcCtD
Nelarabine—Dizziness—Fluorouracil—urinary bladder cancer	3.12e-05	0.000618	CcSEcCtD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—ERBB2—urinary bladder cancer	3.11e-05	0.00085	CbGpPWpGaD
Nelarabine—Mediastinal disorder—Methotrexate—urinary bladder cancer	3.11e-05	0.000616	CcSEcCtD
Nelarabine—Chills—Methotrexate—urinary bladder cancer	3.09e-05	0.000614	CcSEcCtD
Nelarabine—DGUOK—Metabolism—CREBBP—urinary bladder cancer	3.08e-05	0.000842	CbGpPWpGaD
Nelarabine—DCK—Metabolism—TYMP—urinary bladder cancer	3.07e-05	0.000839	CbGpPWpGaD
Nelarabine—Diarrhoea—Cisplatin—urinary bladder cancer	3.06e-05	0.000606	CcSEcCtD
Nelarabine—Vomiting—Gemcitabine—urinary bladder cancer	3.05e-05	0.000604	CcSEcCtD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—PTGS2—urinary bladder cancer	3.04e-05	0.000831	CbGpPWpGaD
Nelarabine—Mental disorder—Methotrexate—urinary bladder cancer	3.02e-05	0.000599	CcSEcCtD
Nelarabine—Eye disorder—Epirubicin—urinary bladder cancer	3.02e-05	0.000598	CcSEcCtD
Nelarabine—ADA—Metabolism—NAT2—urinary bladder cancer	3.01e-05	0.000822	CbGpPWpGaD
Nelarabine—Malnutrition—Methotrexate—urinary bladder cancer	3e-05	0.000595	CcSEcCtD
Nelarabine—Headache—Gemcitabine—urinary bladder cancer	3e-05	0.000595	CcSEcCtD
Nelarabine—Cardiac disorder—Epirubicin—urinary bladder cancer	3e-05	0.000594	CcSEcCtD
Nelarabine—Vomiting—Fluorouracil—urinary bladder cancer	3e-05	0.000594	CcSEcCtD
Nelarabine—Hypoaesthesia—Doxorubicin—urinary bladder cancer	2.97e-05	0.000589	CcSEcCtD
Nelarabine—Headache—Fluorouracil—urinary bladder cancer	2.95e-05	0.000585	CcSEcCtD
Nelarabine—Urinary tract disorder—Doxorubicin—urinary bladder cancer	2.95e-05	0.000585	CcSEcCtD
Nelarabine—Oedema peripheral—Doxorubicin—urinary bladder cancer	2.94e-05	0.000583	CcSEcCtD
Nelarabine—Dysgeusia—Methotrexate—urinary bladder cancer	2.94e-05	0.000583	CcSEcCtD
Nelarabine—Asthenia—Etoposide—urinary bladder cancer	2.94e-05	0.000582	CcSEcCtD
Nelarabine—Connective tissue disorder—Doxorubicin—urinary bladder cancer	2.93e-05	0.000582	CcSEcCtD
Nelarabine—Angiopathy—Epirubicin—urinary bladder cancer	2.93e-05	0.000581	CcSEcCtD
Nelarabine—Urethral disorder—Doxorubicin—urinary bladder cancer	2.93e-05	0.00058	CcSEcCtD
Nelarabine—Mediastinal disorder—Epirubicin—urinary bladder cancer	2.91e-05	0.000577	CcSEcCtD
Nelarabine—POLA1—Mitotic G1-G1/S phases—MYC—urinary bladder cancer	2.91e-05	0.000795	CbGpPWpGaD
Nelarabine—Back pain—Methotrexate—urinary bladder cancer	2.9e-05	0.000576	CcSEcCtD
Nelarabine—Chills—Epirubicin—urinary bladder cancer	2.9e-05	0.000574	CcSEcCtD
Nelarabine—Nausea—Gemcitabine—urinary bladder cancer	2.85e-05	0.000564	CcSEcCtD
Nelarabine—Vomiting—Cisplatin—urinary bladder cancer	2.84e-05	0.000563	CcSEcCtD
Nelarabine—Vision blurred—Methotrexate—urinary bladder cancer	2.83e-05	0.000561	CcSEcCtD
Nelarabine—Mental disorder—Epirubicin—urinary bladder cancer	2.83e-05	0.000561	CcSEcCtD
Nelarabine—Malnutrition—Epirubicin—urinary bladder cancer	2.81e-05	0.000557	CcSEcCtD
Nelarabine—Diarrhoea—Etoposide—urinary bladder cancer	2.8e-05	0.000555	CcSEcCtD
Nelarabine—Nausea—Fluorouracil—urinary bladder cancer	2.8e-05	0.000555	CcSEcCtD
Nelarabine—Eye disorder—Doxorubicin—urinary bladder cancer	2.79e-05	0.000553	CcSEcCtD
Nelarabine—Anaemia—Methotrexate—urinary bladder cancer	2.78e-05	0.00055	CcSEcCtD
Nelarabine—DCK—Metabolism—NAT2—urinary bladder cancer	2.77e-05	0.000758	CbGpPWpGaD
Nelarabine—Cardiac disorder—Doxorubicin—urinary bladder cancer	2.77e-05	0.00055	CcSEcCtD
Nelarabine—Dysgeusia—Epirubicin—urinary bladder cancer	2.75e-05	0.000546	CcSEcCtD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	2.75e-05	0.000751	CbGpPWpGaD
Nelarabine—Back pain—Epirubicin—urinary bladder cancer	2.72e-05	0.000539	CcSEcCtD
Nelarabine—Angiopathy—Doxorubicin—urinary bladder cancer	2.71e-05	0.000537	CcSEcCtD
Nelarabine—Dizziness—Etoposide—urinary bladder cancer	2.71e-05	0.000536	CcSEcCtD
Nelarabine—Mediastinal disorder—Doxorubicin—urinary bladder cancer	2.69e-05	0.000534	CcSEcCtD
Nelarabine—POLA1—Cell Cycle, Mitotic—CCNE1—urinary bladder cancer	2.69e-05	0.000735	CbGpPWpGaD
Nelarabine—Leukopenia—Methotrexate—urinary bladder cancer	2.69e-05	0.000533	CcSEcCtD
Nelarabine—Chills—Doxorubicin—urinary bladder cancer	2.68e-05	0.000531	CcSEcCtD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	2.66e-05	0.000727	CbGpPWpGaD
Nelarabine—Nausea—Cisplatin—urinary bladder cancer	2.65e-05	0.000526	CcSEcCtD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	2.65e-05	0.000725	CbGpPWpGaD
Nelarabine—Vision blurred—Epirubicin—urinary bladder cancer	2.65e-05	0.000525	CcSEcCtD
Nelarabine—POLA1—Cell Cycle, Mitotic—TYMS—urinary bladder cancer	2.64e-05	0.000722	CbGpPWpGaD
Nelarabine—Cough—Methotrexate—urinary bladder cancer	2.62e-05	0.000519	CcSEcCtD
Nelarabine—Mental disorder—Doxorubicin—urinary bladder cancer	2.62e-05	0.000519	CcSEcCtD
Nelarabine—Convulsion—Methotrexate—urinary bladder cancer	2.6e-05	0.000516	CcSEcCtD
Nelarabine—Vomiting—Etoposide—urinary bladder cancer	2.6e-05	0.000516	CcSEcCtD
Nelarabine—Malnutrition—Doxorubicin—urinary bladder cancer	2.6e-05	0.000515	CcSEcCtD
Nelarabine—Anaemia—Epirubicin—urinary bladder cancer	2.6e-05	0.000515	CcSEcCtD
Nelarabine—ADA—Metabolism—RRM2—urinary bladder cancer	2.59e-05	0.000709	CbGpPWpGaD
Nelarabine—ADA—Circadian rythm related genes—TP53—urinary bladder cancer	2.57e-05	0.000703	CbGpPWpGaD
Nelarabine—Headache—Etoposide—urinary bladder cancer	2.56e-05	0.000508	CcSEcCtD
Nelarabine—Myalgia—Methotrexate—urinary bladder cancer	2.56e-05	0.000507	CcSEcCtD
Nelarabine—Arthralgia—Methotrexate—urinary bladder cancer	2.56e-05	0.000507	CcSEcCtD
Nelarabine—Chest pain—Methotrexate—urinary bladder cancer	2.56e-05	0.000507	CcSEcCtD
Nelarabine—Dysgeusia—Doxorubicin—urinary bladder cancer	2.55e-05	0.000505	CcSEcCtD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	2.53e-05	0.000691	CbGpPWpGaD
Nelarabine—DGUOK—Metabolism—PTGS2—urinary bladder cancer	2.52e-05	0.000689	CbGpPWpGaD
Nelarabine—Leukopenia—Epirubicin—urinary bladder cancer	2.52e-05	0.000499	CcSEcCtD
Nelarabine—Back pain—Doxorubicin—urinary bladder cancer	2.51e-05	0.000499	CcSEcCtD
Nelarabine—Confusional state—Methotrexate—urinary bladder cancer	2.47e-05	0.00049	CcSEcCtD
Nelarabine—Loss of consciousness—Epirubicin—urinary bladder cancer	2.47e-05	0.00049	CcSEcCtD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	2.46e-05	0.000672	CbGpPWpGaD
Nelarabine—Cough—Epirubicin—urinary bladder cancer	2.45e-05	0.000486	CcSEcCtD
Nelarabine—Vision blurred—Doxorubicin—urinary bladder cancer	2.45e-05	0.000486	CcSEcCtD
Nelarabine—Convulsion—Epirubicin—urinary bladder cancer	2.43e-05	0.000483	CcSEcCtD
Nelarabine—Infection—Methotrexate—urinary bladder cancer	2.43e-05	0.000483	CcSEcCtD
Nelarabine—Nausea—Etoposide—urinary bladder cancer	2.43e-05	0.000482	CcSEcCtD
Nelarabine—POLA1—Cell Cycle—CCNE1—urinary bladder cancer	2.4e-05	0.000657	CbGpPWpGaD
Nelarabine—Nervous system disorder—Methotrexate—urinary bladder cancer	2.4e-05	0.000476	CcSEcCtD
Nelarabine—Anaemia—Doxorubicin—urinary bladder cancer	2.4e-05	0.000476	CcSEcCtD
Nelarabine—ADA—Metabolism—ENO2—urinary bladder cancer	2.4e-05	0.000657	CbGpPWpGaD
Nelarabine—ADA—Metabolism—HPGDS—urinary bladder cancer	2.4e-05	0.000657	CbGpPWpGaD
Nelarabine—Thrombocytopenia—Methotrexate—urinary bladder cancer	2.4e-05	0.000476	CcSEcCtD
Nelarabine—DCK—Metabolism—RRM2—urinary bladder cancer	2.39e-05	0.000655	CbGpPWpGaD
Nelarabine—POLA1—Mitotic M-M/G1 phases—RB1—urinary bladder cancer	2.39e-05	0.000655	CbGpPWpGaD
Nelarabine—Arthralgia—Epirubicin—urinary bladder cancer	2.39e-05	0.000474	CcSEcCtD
Nelarabine—Chest pain—Epirubicin—urinary bladder cancer	2.39e-05	0.000474	CcSEcCtD
Nelarabine—Myalgia—Epirubicin—urinary bladder cancer	2.39e-05	0.000474	CcSEcCtD
Nelarabine—POLA1—Cell Cycle—TYMS—urinary bladder cancer	2.36e-05	0.000646	CbGpPWpGaD
Nelarabine—Anorexia—Methotrexate—urinary bladder cancer	2.34e-05	0.000463	CcSEcCtD
Nelarabine—ADA—Metabolism—GSTT1—urinary bladder cancer	2.33e-05	0.000637	CbGpPWpGaD
Nelarabine—Leukopenia—Doxorubicin—urinary bladder cancer	2.33e-05	0.000461	CcSEcCtD
Nelarabine—Confusional state—Epirubicin—urinary bladder cancer	2.31e-05	0.000458	CcSEcCtD
Nelarabine—Oedema—Epirubicin—urinary bladder cancer	2.29e-05	0.000455	CcSEcCtD
Nelarabine—Hypotension—Methotrexate—urinary bladder cancer	2.29e-05	0.000454	CcSEcCtD
Nelarabine—Loss of consciousness—Doxorubicin—urinary bladder cancer	2.29e-05	0.000453	CcSEcCtD
Nelarabine—Infection—Epirubicin—urinary bladder cancer	2.28e-05	0.000452	CcSEcCtD
Nelarabine—Cough—Doxorubicin—urinary bladder cancer	2.27e-05	0.00045	CcSEcCtD
Nelarabine—Convulsion—Doxorubicin—urinary bladder cancer	2.25e-05	0.000447	CcSEcCtD
Nelarabine—Nervous system disorder—Epirubicin—urinary bladder cancer	2.25e-05	0.000446	CcSEcCtD
Nelarabine—Thrombocytopenia—Epirubicin—urinary bladder cancer	2.25e-05	0.000445	CcSEcCtD
Nelarabine—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	2.23e-05	0.000443	CcSEcCtD
Nelarabine—DCK—Metabolism—HPGDS—urinary bladder cancer	2.22e-05	0.000606	CbGpPWpGaD
Nelarabine—DCK—Metabolism—ENO2—urinary bladder cancer	2.22e-05	0.000606	CbGpPWpGaD
Nelarabine—Insomnia—Methotrexate—urinary bladder cancer	2.22e-05	0.000439	CcSEcCtD
Nelarabine—Chest pain—Doxorubicin—urinary bladder cancer	2.21e-05	0.000439	CcSEcCtD
Nelarabine—Arthralgia—Doxorubicin—urinary bladder cancer	2.21e-05	0.000439	CcSEcCtD
Nelarabine—Myalgia—Doxorubicin—urinary bladder cancer	2.21e-05	0.000439	CcSEcCtD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	2.2e-05	0.000602	CbGpPWpGaD
Nelarabine—Paraesthesia—Methotrexate—urinary bladder cancer	2.2e-05	0.000436	CcSEcCtD
Nelarabine—DGUOK—Metabolism—PTEN—urinary bladder cancer	2.2e-05	0.000601	CbGpPWpGaD
Nelarabine—Anorexia—Epirubicin—urinary bladder cancer	2.19e-05	0.000433	CcSEcCtD
Nelarabine—Dyspnoea—Methotrexate—urinary bladder cancer	2.18e-05	0.000433	CcSEcCtD
Nelarabine—Somnolence—Methotrexate—urinary bladder cancer	2.18e-05	0.000432	CcSEcCtD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	2.15e-05	0.000589	CbGpPWpGaD
Nelarabine—DCK—Metabolism—GSTT1—urinary bladder cancer	2.15e-05	0.000588	CbGpPWpGaD
Nelarabine—Hypotension—Epirubicin—urinary bladder cancer	2.14e-05	0.000425	CcSEcCtD
Nelarabine—Confusional state—Doxorubicin—urinary bladder cancer	2.14e-05	0.000424	CcSEcCtD
Nelarabine—Decreased appetite—Methotrexate—urinary bladder cancer	2.13e-05	0.000422	CcSEcCtD
Nelarabine—Oedema—Doxorubicin—urinary bladder cancer	2.12e-05	0.000421	CcSEcCtD
Nelarabine—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	2.12e-05	0.000419	CcSEcCtD
Nelarabine—Fatigue—Methotrexate—urinary bladder cancer	2.11e-05	0.000419	CcSEcCtD
Nelarabine—Infection—Doxorubicin—urinary bladder cancer	2.11e-05	0.000418	CcSEcCtD
Nelarabine—DGUOK—Metabolism—EP300—urinary bladder cancer	2.1e-05	0.000573	CbGpPWpGaD
Nelarabine—Pain—Methotrexate—urinary bladder cancer	2.1e-05	0.000415	CcSEcCtD
Nelarabine—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	2.09e-05	0.000414	CcSEcCtD
Nelarabine—Nervous system disorder—Doxorubicin—urinary bladder cancer	2.08e-05	0.000413	CcSEcCtD
Nelarabine—Thrombocytopenia—Doxorubicin—urinary bladder cancer	2.08e-05	0.000412	CcSEcCtD
Nelarabine—Insomnia—Epirubicin—urinary bladder cancer	2.07e-05	0.000411	CcSEcCtD
Nelarabine—Paraesthesia—Epirubicin—urinary bladder cancer	2.06e-05	0.000408	CcSEcCtD
Nelarabine—POLA1—Cell Cycle, Mitotic—CDK4—urinary bladder cancer	2.06e-05	0.000563	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle—TERT—urinary bladder cancer	2.06e-05	0.000562	CbGpPWpGaD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	2.05e-05	0.000561	CbGpPWpGaD
Nelarabine—Dyspnoea—Epirubicin—urinary bladder cancer	2.04e-05	0.000405	CcSEcCtD
Nelarabine—Somnolence—Epirubicin—urinary bladder cancer	2.04e-05	0.000404	CcSEcCtD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	2.04e-05	0.000557	CbGpPWpGaD
Nelarabine—Anorexia—Doxorubicin—urinary bladder cancer	2.02e-05	0.000401	CcSEcCtD
Nelarabine—Feeling abnormal—Methotrexate—urinary bladder cancer	2.02e-05	0.0004	CcSEcCtD
Nelarabine—Gastrointestinal pain—Methotrexate—urinary bladder cancer	2e-05	0.000397	CcSEcCtD
Nelarabine—Decreased appetite—Epirubicin—urinary bladder cancer	1.99e-05	0.000395	CcSEcCtD
Nelarabine—Hypotension—Doxorubicin—urinary bladder cancer	1.98e-05	0.000393	CcSEcCtD
Nelarabine—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	1.98e-05	0.000393	CcSEcCtD
Nelarabine—Fatigue—Epirubicin—urinary bladder cancer	1.98e-05	0.000392	CcSEcCtD
Nelarabine—Constipation—Epirubicin—urinary bladder cancer	1.96e-05	0.000389	CcSEcCtD
Nelarabine—Pain—Epirubicin—urinary bladder cancer	1.96e-05	0.000389	CcSEcCtD
Nelarabine—Body temperature increased—Methotrexate—urinary bladder cancer	1.94e-05	0.000384	CcSEcCtD
Nelarabine—Abdominal pain—Methotrexate—urinary bladder cancer	1.94e-05	0.000384	CcSEcCtD
Nelarabine—ADA—Metabolism—NQO1—urinary bladder cancer	1.94e-05	0.00053	CbGpPWpGaD
Nelarabine—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	1.93e-05	0.000383	CcSEcCtD
Nelarabine—Insomnia—Doxorubicin—urinary bladder cancer	1.92e-05	0.000381	CcSEcCtD
Nelarabine—Paraesthesia—Doxorubicin—urinary bladder cancer	1.91e-05	0.000378	CcSEcCtD
Nelarabine—Dyspnoea—Doxorubicin—urinary bladder cancer	1.89e-05	0.000375	CcSEcCtD
Nelarabine—Feeling abnormal—Epirubicin—urinary bladder cancer	1.89e-05	0.000375	CcSEcCtD
Nelarabine—Somnolence—Doxorubicin—urinary bladder cancer	1.89e-05	0.000374	CcSEcCtD
Nelarabine—Gastrointestinal pain—Epirubicin—urinary bladder cancer	1.88e-05	0.000372	CcSEcCtD
Nelarabine—POLA1—Cell Cycle—ATM—urinary bladder cancer	1.85e-05	0.000506	CbGpPWpGaD
Nelarabine—Decreased appetite—Doxorubicin—urinary bladder cancer	1.84e-05	0.000366	CcSEcCtD
Nelarabine—POLA1—Cell Cycle—CDK4—urinary bladder cancer	1.84e-05	0.000503	CbGpPWpGaD
Nelarabine—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	1.83e-05	0.000363	CcSEcCtD
Nelarabine—Fatigue—Doxorubicin—urinary bladder cancer	1.83e-05	0.000363	CcSEcCtD
Nelarabine—Pain—Doxorubicin—urinary bladder cancer	1.81e-05	0.00036	CcSEcCtD
Nelarabine—Constipation—Doxorubicin—urinary bladder cancer	1.81e-05	0.00036	CcSEcCtD
Nelarabine—Body temperature increased—Epirubicin—urinary bladder cancer	1.81e-05	0.000359	CcSEcCtD
Nelarabine—Abdominal pain—Epirubicin—urinary bladder cancer	1.81e-05	0.000359	CcSEcCtD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	1.81e-05	0.000495	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle, Mitotic—RB1—urinary bladder cancer	1.79e-05	0.00049	CbGpPWpGaD
Nelarabine—DCK—Metabolism—NQO1—urinary bladder cancer	1.79e-05	0.000489	CbGpPWpGaD
Nelarabine—Asthenia—Methotrexate—urinary bladder cancer	1.76e-05	0.000349	CcSEcCtD
Nelarabine—Feeling abnormal—Doxorubicin—urinary bladder cancer	1.75e-05	0.000347	CcSEcCtD
Nelarabine—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	1.74e-05	0.000344	CcSEcCtD
Nelarabine—Abdominal pain—Doxorubicin—urinary bladder cancer	1.68e-05	0.000333	CcSEcCtD
Nelarabine—Body temperature increased—Doxorubicin—urinary bladder cancer	1.68e-05	0.000333	CcSEcCtD
Nelarabine—Diarrhoea—Methotrexate—urinary bladder cancer	1.68e-05	0.000332	CcSEcCtD
Nelarabine—Asthenia—Epirubicin—urinary bladder cancer	1.65e-05	0.000326	CcSEcCtD
Nelarabine—Dizziness—Methotrexate—urinary bladder cancer	1.62e-05	0.000321	CcSEcCtD
Nelarabine—ADA—Metabolism—GSTP1—urinary bladder cancer	1.62e-05	0.000442	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle—RB1—urinary bladder cancer	1.6e-05	0.000438	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle, Mitotic—CDKN2A—urinary bladder cancer	1.57e-05	0.00043	CbGpPWpGaD
Nelarabine—Diarrhoea—Epirubicin—urinary bladder cancer	1.57e-05	0.000311	CcSEcCtD
Nelarabine—Vomiting—Methotrexate—urinary bladder cancer	1.56e-05	0.000309	CcSEcCtD
Nelarabine—Headache—Methotrexate—urinary bladder cancer	1.54e-05	0.000304	CcSEcCtD
Nelarabine—Asthenia—Doxorubicin—urinary bladder cancer	1.52e-05	0.000302	CcSEcCtD
Nelarabine—Dizziness—Epirubicin—urinary bladder cancer	1.52e-05	0.000301	CcSEcCtD
Nelarabine—ADA—Metabolism—TYMS—urinary bladder cancer	1.5e-05	0.000411	CbGpPWpGaD
Nelarabine—DCK—Metabolism—GSTP1—urinary bladder cancer	1.49e-05	0.000408	CbGpPWpGaD
Nelarabine—ADA—Metabolism—GSTM1—urinary bladder cancer	1.48e-05	0.000406	CbGpPWpGaD
Nelarabine—ADA—Metabolism—NCOR1—urinary bladder cancer	1.48e-05	0.000406	CbGpPWpGaD
Nelarabine—Vomiting—Epirubicin—urinary bladder cancer	1.46e-05	0.000289	CcSEcCtD
Nelarabine—Nausea—Methotrexate—urinary bladder cancer	1.46e-05	0.000289	CcSEcCtD
Nelarabine—Diarrhoea—Doxorubicin—urinary bladder cancer	1.45e-05	0.000288	CcSEcCtD
Nelarabine—Headache—Epirubicin—urinary bladder cancer	1.44e-05	0.000285	CcSEcCtD
Nelarabine—ADA—Metabolism—GPX1—urinary bladder cancer	1.42e-05	0.000389	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle—CDKN2A—urinary bladder cancer	1.41e-05	0.000385	CbGpPWpGaD
Nelarabine—Dizziness—Doxorubicin—urinary bladder cancer	1.4e-05	0.000278	CcSEcCtD
Nelarabine—ADA—Metabolism—ERCC2—urinary bladder cancer	1.4e-05	0.000382	CbGpPWpGaD
Nelarabine—DCK—Metabolism—TYMS—urinary bladder cancer	1.39e-05	0.000379	CbGpPWpGaD
Nelarabine—DCK—Metabolism—GSTM1—urinary bladder cancer	1.37e-05	0.000375	CbGpPWpGaD
Nelarabine—DCK—Metabolism—NCOR1—urinary bladder cancer	1.37e-05	0.000375	CbGpPWpGaD
Nelarabine—Nausea—Epirubicin—urinary bladder cancer	1.36e-05	0.00027	CcSEcCtD
Nelarabine—Vomiting—Doxorubicin—urinary bladder cancer	1.35e-05	0.000267	CcSEcCtD
Nelarabine—POLA1—Cell Cycle, Mitotic—CCND1—urinary bladder cancer	1.33e-05	0.000364	CbGpPWpGaD
Nelarabine—Headache—Doxorubicin—urinary bladder cancer	1.33e-05	0.000264	CcSEcCtD
Nelarabine—ADA—Metabolism—MTHFR—urinary bladder cancer	1.31e-05	0.000359	CbGpPWpGaD
Nelarabine—DCK—Metabolism—GPX1—urinary bladder cancer	1.31e-05	0.000359	CbGpPWpGaD
Nelarabine—DCK—Metabolism—ERCC2—urinary bladder cancer	1.29e-05	0.000352	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle, Mitotic—CDKN1A—urinary bladder cancer	1.29e-05	0.000352	CbGpPWpGaD
Nelarabine—Nausea—Doxorubicin—urinary bladder cancer	1.26e-05	0.00025	CcSEcCtD
Nelarabine—POLA1—Cell Cycle, Mitotic—EP300—urinary bladder cancer	1.22e-05	0.000335	CbGpPWpGaD
Nelarabine—DCK—Metabolism—MTHFR—urinary bladder cancer	1.21e-05	0.000331	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle—CCND1—urinary bladder cancer	1.19e-05	0.000325	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle—CDKN1A—urinary bladder cancer	1.15e-05	0.000314	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle—EP300—urinary bladder cancer	1.09e-05	0.000299	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle, Mitotic—MYC—urinary bladder cancer	1.07e-05	0.000292	CbGpPWpGaD
Nelarabine—ADA—Metabolism—PPARG—urinary bladder cancer	1.06e-05	0.000291	CbGpPWpGaD
Nelarabine—ADA—Metabolism—CREBBP—urinary bladder cancer	1.02e-05	0.000279	CbGpPWpGaD
Nelarabine—DCK—Metabolism—PPARG—urinary bladder cancer	9.82e-06	0.000268	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle—MYC—urinary bladder cancer	9.54e-06	0.000261	CbGpPWpGaD
Nelarabine—DCK—Metabolism—CREBBP—urinary bladder cancer	9.43e-06	0.000258	CbGpPWpGaD
Nelarabine—ADA—Metabolism—PTGS2—urinary bladder cancer	8.37e-06	0.000229	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle—TP53—urinary bladder cancer	7.83e-06	0.000214	CbGpPWpGaD
Nelarabine—DCK—Metabolism—PTGS2—urinary bladder cancer	7.72e-06	0.000211	CbGpPWpGaD
Nelarabine—ADA—Metabolism—PTEN—urinary bladder cancer	7.3e-06	0.0002	CbGpPWpGaD
Nelarabine—ADA—Metabolism—EP300—urinary bladder cancer	6.96e-06	0.00019	CbGpPWpGaD
Nelarabine—DCK—Metabolism—PTEN—urinary bladder cancer	6.74e-06	0.000184	CbGpPWpGaD
Nelarabine—DCK—Metabolism—EP300—urinary bladder cancer	6.42e-06	0.000176	CbGpPWpGaD
